A Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in Refractory Metastatic GIST
The purpose of this study is to determine whether dasatinib is effective and safe in the treatment of refractory metastatic gastrointestinal stromal tumor
Gastrointestinal Stromal Tumor
DRUG: dasatinib
Progression-free survive, calculated from registration until progression or death, 2 years
Overall survival, overall survival will be calculated from registration until death, 2 years|Adverse drug reactions according to NCI CTCAE v4.0, 2 years, Tolerability will be assessed based on the frequency and severity of Adverse Drug Reactions (ADR) coded according to NCI CTCAE v4.0.|Objective response, according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria, 2 years|Tumor control probability, defined as CR＋PR＋SD, determined according to RECIST 1.1 criteria, 2 years
The purpose of this study is to determine whether dasatinib is effective and safe in the treatment of refractory metastatic gastrointestinal stromal tumor